TD Private Client Wealth LLC Increases Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

TD Private Client Wealth LLC grew its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 22.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,099 shares of the company’s stock after buying an additional 388 shares during the period. TD Private Client Wealth LLC’s holdings in Amphastar Pharmaceuticals were worth $78,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in AMPH. Smartleaf Asset Management LLC raised its holdings in Amphastar Pharmaceuticals by 222.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after acquiring an additional 493 shares during the last quarter. Parkside Financial Bank & Trust increased its holdings in shares of Amphastar Pharmaceuticals by 806.5% in the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock worth $36,000 after purchasing an additional 871 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. raised its stake in shares of Amphastar Pharmaceuticals by 53.4% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after purchasing an additional 398 shares during the last quarter. KBC Group NV lifted its holdings in shares of Amphastar Pharmaceuticals by 43.1% during the fourth quarter. KBC Group NV now owns 2,159 shares of the company’s stock valued at $80,000 after purchasing an additional 650 shares in the last quarter. Finally, Point72 DIFC Ltd boosted its position in shares of Amphastar Pharmaceuticals by 85.9% during the third quarter. Point72 DIFC Ltd now owns 3,954 shares of the company’s stock valued at $192,000 after buying an additional 1,827 shares during the last quarter. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Price Performance

NASDAQ AMPH opened at $28.39 on Wednesday. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of 9.46, a PEG ratio of 2.19 and a beta of 0.77. Amphastar Pharmaceuticals, Inc. has a 1-year low of $25.89 and a 1-year high of $53.96. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The business’s fifty day moving average price is $31.52 and its 200-day moving average price is $40.24.

Analysts Set New Price Targets

Separately, Piper Sandler decreased their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research report on Friday, March 21st.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of the company’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares of the company’s stock, valued at $2,681,377.02. This represents a 4.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 27.10% of the stock is owned by corporate insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.